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A methodology (HPLC) proposed in this paper for simultaneously quantitative determi-
nation of ilaprazole and its related impurities in commercial tablets was developed and
validated. The chromatographic separation was carried out by gradient elution using an
Agilent C8 column (4.6 mm  250 mm, 5 mm) which was maintained at 25 C. The mobile
phase composed of solvent A (methanol) and solvent B (solution consisting 0.02 mmol/l
monopotassium phosphate and 0.025 mmol/l sodium hydroxide) was at a flow rate of
1.0 ml/min. The samples were detected and quantified at 237 nm using an ultraviolet
absorbance detector. Calibration curves of all analytes from 0.5 to 3.5 mg/ml were good
linearity (r  0.9990) and recovery was greater than 99.5% for each analyte. The lower limit
of detection (LLOD) and quantification (LOQ) of this analytical method were 10 ng/ml and
25 ng/ml for all impurities, respectively. The stress studies indicated that the degradation
products could not interfere with the detection of ilaprazole and its related impurities and
the assay can thus be considered stability-indicating. The method precisions were in the
range of 0.41e1.21 while the instrument precisions were in the range of 0.38e0.95 in terms
of peak area RSD% for all impurities, respectively. This method is considered stability-
indicating and is applicable for accurate and simultaneous measuring of the ilaprazole
and its related impurities in commercial enteric-coated tablets.
© 2015 Shenyang Pharmaceutical University. Production and hosting by Elsevier B.V. This is
an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).1. Introduction
Ilaprazole, [IY-81149, 2 (((4-methoxy-3-methyl)-2-pyridinyl)-




ns.org/licenses/by-nc-ndis a potent inhibitor of the enzyme gastric proton pump
Hþ/Kþ-ATPase in inhibiting gastric acid secretion, which in-
cludes gastric and duodenal ulcer, reflux oesophagitis and
Zollinger-Ellison syndrome [1e3]. Unlike other proton pump, Wenhua Road, Shenyang 110016, China. Tel.: þ86 24 23986293/
sity.
d hosting by Elsevier B.V. This is an open access article under the
/4.0/).
Fig. 1 e Chemical structures of (A) ilaprazole, (B) ilaprazole sulfur ether and (C) ilaprazole sulphone.
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(about 3.6 h) [4] produces a greater and prolongs acid-
suppressing effect [5], avoiding the occurrence of nocturnal
acid break (NAB) during the PPIs therapy [6]. Besides, a greater
safety could be assured by at least two factors. One is the sig-
nificant reduction of dosage and lower toxicity for ilaprazole
comparing to omeprazole [7]. And the other one is the low
variability of the pharmacokinetics and pharmacodynamics of
ilaprazole attributed to its metabolism independent of
CYP2C19 [8], which played the predominant role in meta-
bolism of other PPIs [9,10].
Recently, there were a lot of efforts committed to
researching metabolism in vivo [11e14]; however, there was
only one paper reporting a UPLCmethod for the simultaneous
determination of ilaprazole and its impurities in tablets [15]. A
ternary liquid system (acetonitrile, methanol and ammonium
acetate buffer) was used to separated five known impurities.
In light of the requirements of amorewidely availablemethod
and better quality control for ilaprazole involved solid prepa-
rations, the development of a novel analytical method was
demanded and necessary. Therefore, we developed a sensi-
tive, selective and accurate gradient HPLC method, using a
simple methanol-water binary system, for the quantification
of ilaprazole and seven known impurities including ilaprazole
sulfur ether and ilaprazole sulphone (Fig. 1B and C) and im-
purity A, B, C, D, E (structures not for publication) in com-
mercial tablets.2. Materials and methods
2.1. Materials
Ilaprazole (5 mg enteric-coated tablet) were purchased from
Liyzon Pharmaceutical Group Inc. (Zhuhai, China). Ilaprazole
and related impurities (ilaprazole sulphone, ilaprazole sulfur
ether and impurity A, B, C, D, and E) (purity > 99.0%, purities
were detected by HPLC using area normalization method and
structures were validated by nuclear magnetism resonance
(NMR) and mass spectrum (MS)) were supplied by MedicinalChemistry Lab of Shenyang Pharmaceutical University (She-
nyang, China). HPLC-grade methanol was from Fisher Scien-
tific Worldwide (Shanghai) Co., Ltd. (Shanghai, China).
Deionized-distilled water was used throughout this study.
All other reagents were of analytical grade.
2.2. HPLC operating conditions
HPLC separations were performed by an Agilent C8 column
(4.6 mm  250 mm, 5 mm) (Agilent, USA). Analytical HPLC
apparatus was consisted of an L-2130 pump (Hitachi, Japan)
and an L-2400 ultraviolet absorbance detector (Hitachi, Japan).
Gradient HPLC method was used for the analysis of ilap-
razole and its related impurities at 25 C by using an ultravi-
olet absorbance detector at a wavelength of 237 nm. The
mobile phase consisted of solvent A (methanol) and solvent B
(0.02 mmol/l monopotassium phosphate and 0.025 mmol/l
sodium hydroxide) with a flow rate of 1.0 ml/min. The initial
mobile phase composition was maintained at 42% solvent A
for 30 min, changed linearly to 55% (30e35 min) and held
30 min (35e65 min), then followed by a return to the initial
conditions within 5 min (65e70 min) and kept 5 min
(70e75 min) for the chromatograph column equilibrium. The
mobile phase was filtered through a 0.22 mm PTFE filter (Mil-
lipore, USA) and ultrasounded for degasification before use.
The injection volume was of 20 ml.
2.3. Preparation of stock and standard solutions
On account of the instability of ilaprazole, its freshly solution
was prepared immediately before use and protected from
light. Stock solutions (100 mg/ml) of ilaprazole impurities were
separately prepared with methanol. The stock solutions of
different impurity were kept from light and stored at 4 C for
four weeks with no evidence of decomposition.
Aliquots of the stock solutions of different impurity were
transferred into 10ml volumetric flaskswith bulb pipettes and
the solutions were made up to volume with methanol to yield
final concentrations of 0.5, 1, 1.5, 2, 2.5, 3 and 3.5 mg/ml for
each impurity.
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mixedwith amortar and pestle for 15min. A portion of powder
equivalent to 10 mg ilaprazole was precisely weighed to 10 ml
volumetric flask and 5mlmethanolwas added. The volumetric
flaskwas sonicated for 10min to completely dissolve ilaprazole
and then the solutionsweremadeup to volumewithmethanol.
After centrifugation for 5 min at 13,000 rpm, aliquots of the
solutions were filtered through 0.22 mm nylon filters.
2.4. System suitability test
System suitability test was conducted by injections of the
system suitability solution (n ¼ 6). The acceptance criteria
were as follows: relative standard deviation (RSD) for peak
areas within 2%, column plates greater than 5000, the USP
tailing factor within 1.5, and the resolution greater than 2.0.
2.5. Forced degradation studies of ilaprazole
The conditions for forced degradation studies were screened
and finally fixed as follows to obtain 10e20% degradation of
ilaprazole [16].
2.5.1. Acid degradation
Solution containing 1 mg/ml of ilaprazole was treated with
1 mol/l HCl for 30 s. The resultant solution was neutralized
immediately as needed and analyzed.
2.5.2. Alkali degradation
Solution containing 1 mg/ml of ilaprazole was disposed with
1mol/l NaOH for 2 h. The resultant solutions were neutralized
and analyzed promptly.
2.5.3. Oxidative condition
Solution containing 1mg/ml ilaprazolewas obtainedwith 30%
w/v H2O2, and the resultant solutions were analyzed 1 h later.
2.5.4. Thermal degradation study
Tablet powderswere subjected to 100 C in an oven for 1 h, and
then 1mg/ml ilaprazole solution was achieved withmethanol
for analysis.
2.5.5. Photostability study
Tablet powders were exposed to 4500 lx ± 500 lx light for 20
days to determine the effect of irradiation on the stability of
the drug. The sample solution (equivalent to approximately
1mg/ml of ilaprazole) was prepared for further HPLC analysis.Fig. 2 e Chromatogram of the system suitability test
solution (1-Impurity A, 2-Impurity C, 3-Impurity D, 4-
Impurity E, 5-Ilaprazole sulphone, 6-Ilaprazole, 7-Impurity
B, 8-Ilaprazole sulfur ether).3. Results and discussion
3.1. HPLC method development and optimization
As we all know, more impurities controlled were beneficial to
guarantee quality of commercial drugs and to ensure safety of
drug therapy. From this prespective, the development of
method with a capability of more known impurities detected
than the reported method in the literature [15] was necessary
and salutary. At the begin of method development, an iso-
cratic elution (42% solvent A as the initial mobile phasecomposition described in section “2.2”) was used to separate
ilaprazole and seven kown impurities, leading to a total run-
time over 120 min. Considering the polarity difference of
ilaprazole and its related impurities, a gradient HPLC method
was developed to achieve a shorter runtime and desired
sensitivity. An Agilent C8 column (4.6 mm  250 mm, 5 mm)
(Agilent, USA)maintained at 25 Cwas used for the separation
and this method was validated to assure the reliability of
determination of ilaprazole and its impurities. The composi-
tion, pH and the flow rate of themobile phasewere changed to
optimize the separation conditions. A gradient HPLC method
which was described in section “2.2” was selected for further
studies after several preliminary investigatory chromato-
graphic runs. Under the experimental conditions, all the
peaks were well defined and free from tailing. The deliberate
changes in the mobile phase composition and flow rate were
evaluated to test the method robustness.
3.2. Validation of the method
The developed method was characterized by evaluation of
specificity, limit of detection (LLOD), limit of quantization
(LOQ), linearity, precision, accuracy, and robustness/
ruggedness.
3.2.1. System suitability test
The results of system suitability test indicated that all the
parameters obtained were within the acceptable limits. Fig. 2
shows the chromatogram of the system suitability test
solution.
3.2.2. Specificity
The specificity of the method was guaranteed by observing
potential interferences caused by degradation products under
stress conditions. The stress testing studies indicated a pref-
erable specificity of this method for both ilaprazole and its
related impurities. The results of stress testing are shown in
Fig. 3.
3.2.3. LLOD and LOQ
The LOQs for ilaprazole impurity A, B, C, D, E, ilaprazole sul-
phone and ilaprazole sulfur ether corresponding to a signal-
to-noise ratio of 10 were 25 ng/ml, 200 ng/ml, 75 ng/ml,
125 ng/ml, 750 ng/ml, 200 ng/ml and 200 ng/ml, respectively.
Fig. 3 e Chromatograms of stress test. (A) Untreated tablet powders; (B) acid hydrolysis-degraded tablet powders; (C) base
hydrolysis-degraded tablet powders; (D) dry-heated tablet powders; (E) light degraded tablet powders; (F) oxidation
degraded tablet powders (the peak number is the same as in Fig. 2).
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to a signal-to-noise ratio of 3 were 10 ng/ml, 80 ng/ml,
30 ng/ml, 50 ng/ml, 300 ng/ml, 80 ng/ml and 80 ng/ml. The
resultant RSD values (%) for these studies were 2.0%.
3.2.4. Linearity
The linearity was performed with the standard solutions of
ilaprazole impurities (n ¼ 7) over the concentration range of
0.5e3.5 mg/ml, respectively. Least squares linear regressionTable 1 e Typical sequent regression equations of
ilaprazole related impurities.
Compound Regression equation Correlation
coefficient (r)
Impurity A A ¼ 147.39C  5162.7 0.9997
Impurity B A ¼ 84.09C  2570.1 0.9999
Impurity C A ¼ 95.128C  2427.7 0.9996
Impurity D A ¼ 102.61C  2903.1 0.9999
Impurity E A ¼ 14.371C þ 701.86 0.9994
Ilaprazole
sulphone
A ¼ 70.984C  2730.1 0.9992
Ilaprazole
sulfur ether
A ¼ 107.66C  3309.3 0.9990
Note: A being the peak area and C the concentration in mg/ml.analysis of the calibration curve was employed to establish
the linearity. Typical sequent regression equations for ilap-
razole impurity A, B, C, D, E, ilaprazole sulphone and ilapra-
zole sulfur ether are listed in Table 1.
3.2.5. Precision
The precision of the HPLCmethodwere assessed by analyzing
6 replicate sample solutions in three different concentrations
of mixed impurities standard solutions (i.e. 0.8, 1.0, 1.2 mg/ml).
The same sample solution (1.0 mg/ml) was injected 6 times to








Impurity A 0.41 0.38
Impurity B 0.69 0.44
Impurity C 1.09 0.85
Impurity D 0.85 0.42
Impurity E 1.21 0.95
Ilaprazole sulphone 0.71 0.51
Ilaprazole sulfur ether 0.68 0.78
Table 3 e Accuracy results for the determination of ilaprazole related impurities.
Compound Added (mg/ml) Found (mg/ml) Recovery (%) RSD (%) Average recovery (%) Average RSD (%)
Impurity A 0.80 0.80 99.8 0.54 99.8 0.61
1.00 1.00 99.9 0.31
1.20 1.20 99.7 0.98
Impurity B 0.80 0.80 100.5 1.08 100.3 0.92
1.00 1.00 100 0.86
1.20 1.21 100.5 0.82
Impurity C 0.80 0.80 100.2 0.28 100.2 0.34
1.00 1.00 100.3 0.32
1.20 1.20 100.2 0.43
Impurity D 0.80 0.80 100 0.70 99.8 0.54
1.00 1.00 99.8 0.49
1.20 1.19 99.5 0.43
Impurity E 0.80 0.81 100.5 1.21 100.2 0.87
1.00 1.00 99.8 0.45
1.20 1.21 100.4 0.96
Ilaprazole sulphone 0.80 0.81 100.9 0.42 100.7 0.37
1.00 1.00 100.3 0.16
1.20 1.21 100.9 0.51
Ilaprazole sulfur ether 0.80 0.80 99.7 1.19 99.8 1.01
1.00 1.00 100 0.94
1.20 1.20 99.8 0.88
Table 5 e Results of stability of ilaprazole related
impurities solution at ambient temperature.
Compound Rate of change (%)of different impurity
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less than 1.21 and 0.95% for impurities A, B, C, D, E, ilaprazole
sulphone and ilaprazole sulfur ether (Table 2).
3.2.6. Accuracy
Results of method accuracy are summarized in Table 3. The
accuracy for the determination of ilaprazole and its impurities
was determined by preparing drug substance sample at 80,
100 and 120% of the target (1 mg/ml). The apparent recovery of
ilaprazole and its impurities were found to be from 99.5 to
100.9%. The average percent recovery was 99.8 (RSD% 0.61),
100.3 (RSD% 0.92), 100.2% (RSD% 0.34), 99.8% (RSD% 0.54),
100.2% (RSD% 0.87), 100.7% (RSD% 0.37) and 99.8% (RSD% 1.01)
for ilaprazole and its related impurities.
3.2.7. Stability
The stability of ilaprazole in methanol was evaluated at
ambient temperature and 4 C in refrigeration for 12 h (Table
4). Compared with ambient temperature, the stability of
sample was improved to some extent, however, the change
of ilaprazole peak area was approximated 2% in 2 h, so the
fresh sample needed to be prepared prior to use. The mixed
impurities solution was stable at ambient temperature for
12 h (Table 5). No significant changes (<2%) of the chro-
matographic responses were observed for the stockTable 4 e Results of stability of ilaprazole solution at
ambient temperature and 4 C.
Conditions Rate of change (%) of ilaprazole peak
area under different conditions
2 h 4 h 6 h 8 h 10 h 12 h
Ambient
temperature
2.91 4.44 6.79 8.87 11.01 13.40
4 C 1.84 3.13 5.50 5.64 7.78 10.17solutions of different impurity, relative to freshly prepared
standards (Table 6).
3.2.8. Robustness
The robustness of the HPLC method was studied under a va-
riety of conditions including changes of flow rate and the
proportion of buffer and organic phase. The small deliberate
variations of these parameters were not significantly affected
the reproducibility of the proposed method, which proved
good robustness of the HPLC method.4. Conclusions
A sensitive, selective and accurate gradient HPLC method has
been developed and validated for the quantization of ilapra-
zole and its related impurities in commercial tablets. The
stress testing results revealed that the method was specific
and selective. Validation experiments demonstrated that
linear, precise and accurate of method met the acceptancepeak area at ambient temperature
2 h 4 h 6 h 8 h 10 h 12 h
Impurity A 0.67 0.97 0.38 0.30 0.77 0.45
Impurity B 0.56 0.34 0.59 0.89 0.98 0.37
Impurity C 0.22 0.06 0.77 0.78 0.76 0.66
Impurity D 0.54 0.54 0.92 0.79 0.77 0.59
Impurity E 0.70 0.11 0.87 0.08 0.82 0.31
Ilaprazole
sulphone
0.65 0.35 0.60 0.21 0.27 0.50
Ilaprazole
sulfur ether
0.57 0.45 0.59 0.24 0.26 0.47
Table 6 e Results of stability of the stock solutions of different impurity at 4 C for four weeks.
Compound Impurity A Impurity B Impurity C Impurity D Impurity E Ilaprazole sulphone Ilaprazole sulfur ether
Rate of change (%) 0.48 0.17 0.41 0.39 0.64 0.37 0.85
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for quantitation of ilaprazole and its related impurities in
commercial enteric-coated tablets.r e f e r e n c e s
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